SERF2-C15ORF63: A Potential Drug Target and Biomarker (G100529067)

Target Name: SERF2-C15ORF63

NCBI ID: G100529067

SERF2-C15ORF63

Other Name(s): HYPK | C15orf63 | SERF2-C15orf63 readthrough

SERF2-C15ORF63: A Potential Drug Target and Biomarker

Serf2 (Sarcomere-associated protein 2) is a protein that plays a critical role in the regulation of cell division and cytoskeletal organization. It is a member of the superfamily of cytoskeleton-associated proteins (SAPs) and is involved in various cellular processes, including cell division, migration, and cytoskeletal organization. The SERF2 gene has four exons, and the encoded protein has 15 unique amino acid residues and 63% amino acid sequence identity with the protein SERF2-C15ORF62. SERF2-C15ORF63 is a potential drug target and biomarker because of its involvement in various cellular processes and its unique amino acid sequence.

Potential Drug Target

SERF2 is a protein that is known to play a critical role in the regulation of cell division and cytoskeletal organization. It is involved in the formation of the cytoskeleton, which is the structure that organizes the cell's components during cell division and other cellular processes. Therefore, targeting SERF2 could be a potential drug target for various diseases, including cancer.

Serf2 is involved in the regulation of cell division by activating the G1 checkpoint, which is a critical step in the cell cycle that prevents the cell from entering the G2 phase and cycling through the DNA replication process. Activation of the G1 checkpoint allows the cell to prepare for cell division by producing more organelles and increasing the size of the cell.

In addition to its role in cell division, SERF2 is also involved in the regulation of cytoskeletal organization. It plays a critical role in the formation of the microtubules that organize the cell's mitochondria and other organelles. Therefore, targeting SERF2 with drugs could potentially disrupt the organization of the cell's cytoskeleton, leading to various cellular changes that could be harmful to the cell.

Potential Biomarker

SERF2 is also a potential biomarker for various diseases. Its involvement in the regulation of cell division and cytoskeletal organization makes it a potential target for drugs that aim to treat diseases that are characterized by abnormal cell division or disrupted cytoskeletal organization.

For example, SERF2 has been shown to be involved in the regulation of cancer cell division. Studies have shown that cancer cells often have increased levels of SERF2 and that inhibition of SERF2 has the potential to disrupt the growth and proliferation of cancer cells. Additionally, SERF2 has been shown to be involved in the regulation of normal cell division, and alterations in SERF2 levels have been observed in various diseases, including Alzheimer's disease and Parkinson's disease.

Conclusion

In conclusion, SERF2 is a protein that is involved in various cellular processes and has been shown to play a critical role in the regulation of cell division and cytoskeletal organization. As a potential drug target and biomarker, targeting SERF2 with drugs could have significant implications for the treatment of various diseases. Further research is needed to fully understand the role of SERF2 in cellular processes and its potential as a drug target and biomarker.

Protein Name: SERF2-C15orf63 Readthrough

The "SERF2-C15ORF63 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SERF2-C15ORF63 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets